Content about Headache

September 26, 2013

As many as 95% of consumers have suffered from either a cold, flu or allergy ailments or has a family member who has suffered in the past year, according to an online survey of more than 500 AccentHealth viewers conducted in August. Of those consumers, 84% suffered from seasonal or outdoor allergies, 82% from sinus congestion or headache, 72% from cold symptoms and 28% from flu symptoms. To see more Patient Views, click here.

July 12, 2013

Prestige Brands is the first over-the-counter manufacturer to adopt an "energy shot" format in an effort to infuse differentiation into the brand.

TARRYTOWN, N.Y. — Prestige Brands is the first over-the-counter manufacturer to adopt an "energy shot" format in an effort to infuse differentiation into the brand. And while Goody's Headache Relief Shot may stand out on store shelves as one of the first liquid analgesics targeting adults, it will not stay on those shelves for long. Sales of Goody's Headache Powder already were up 9.4% to $37.5 million for the 52 weeks ended May 19 across total U.S. multi-outlet, according to IRI data, well outpacing category growth of 0.2%.

May 21, 2013

Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

HAYWARD, Calif. — Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.

Impax said its generics division, Global Pharmaceuticals, began shipping authorized generic zolmitriptan tablets and orally disintegrating tablets in the 2.5 mg and 5 mg strengths. The drug is a version of AstraZeneca's Zomig.

Zomig had sales of about $196 million during the 12-month period that ended in April, according to IMS Health.

November 28, 2012

Consumers are increasingly turning to OTCs to treat their conditions, including both acute, episodic conditions like the common cold and such chronic conditions as frequent pain and allergy. However, the extent to which OTCs are used varies by condition, according to an online survey of more than 900 AccentHealth viewers conducted in September. Headache sufferers reported using OTC medications most often (89%), while sufferers of certain digestive disorders use OTCs less often (53%).

Consumers are increasingly turning to OTCs to treat their conditions, including both acute, episodic conditions like the common cold and such chronic conditions as frequent pain and allergy. However, the extent to which OTCs are used varies by condition, according to an online survey of more than 900 AccentHealth viewers conducted in September. Headache sufferers reported using OTC medications most often (89%), while sufferers of certain digestive disorders use OTCs less often (53%).

To see more Patient Views, click here.

September 14, 2012

The Food and Drug Administration has granted regulatory approval for a generic drug to treat tension headaches.

PHILADELPHIA — The Food and Drug Administration has granted regulatory approval for a generic drug to treat tension headaches.

Lannett announced the approval of butalbital, acetaminophen and caffeine tablets in the 50-mg/325-mg/40-mg strength. the drug is a generic version of Watson Pharmaceuticals' Fioricet.

Branded and generic versions of the drug had sales of $30 million during the 12-month period ended in July, including $15 million for branded Fioricet. Lannett plans to start shipping its version next month, the company said.